Autenticati per visualizzare i prezzi organizzativi e contrattuali.
Scegli un formato
Cambia visualizzazione
| Taglio della confezione | SKU | Disponibilità | Prezzo |
|---|---|---|---|
| 500 mg | Per conoscere la disponibilità, visualizza il carrello | CHF 488.00 CHF 366.00 |
Informazioni su questo articolo
Formula empirica (notazione di Hill):
C32H56N2O2
Numero CAS:
Peso molecolare:
500.80
UNSPSC Code:
12352211
PubChem Substance ID:
NACRES:
NA.85
CHF 366.00
Prezzo di listinoCHF 488.00Risparmia il 25%Promozione valida solo online
Per conoscere la disponibilità, visualizza il carrello
Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutartiQuality Level
assay
≥98% (TLC)
form
powder or crystals
functional group
ester
storage temp.
−20°C
SMILES string
CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4CC(CC[C@]4(C)[C@H]3CC[C@]12C)OC(=O)NCCN(C)C
InChI
1S/C32H56N2O2/c1-22(2)9-8-10-23(3)27-13-14-28-26-12-11-24-21-25(36-30(35)33-19-20-34(6)7)15-17-31(24,4)29(26)16-18-32(27,28)5/h11,22-23,25-29H,8-10,12-21H2,1-7H3,(H,33,35)/t23-,25?,26+,27-,28+,29+,31+,32-/m1/s1
InChI key
HIHOWBSBBDRPDW-MTIZRNOUSA-N
Application
- Role of interleukin-6 in antigen-specific mucosal immunoglobulin A induction by cationic liposomes.: This study investigates the use of cholesteryl N-(2-dimethylaminoethyl)carbamate in cationic liposomes for enhancing mucosal immunoglobulin A production, highlighting its potential in vaccine development (Tada et al., 2021).
- Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice.: This research demonstrates the efficacy of cholesteryl N-(2-dimethylaminoethyl)carbamate in nasal vaccines, providing a promising strategy for respiratory infection prevention (Tada et al., 2018).
Biochem/physiol Actions
Packaging
Bottomless glass bottle. Contents are inside inserted fused cone.
1 of 1
Questo articolo | |||
|---|---|---|---|
| functional group ester | functional group ester | functional group - | functional group - |
| assay ≥98% (TLC) | assay ≥98% (TLC) | assay ≥95% | assay ≥98% (TLC) |
| form powder or crystals | form powder | form powder | form powder |
| storage temp. −20°C | storage temp. −20°C | storage temp. −20°C | storage temp. −20°C |
| Quality Level 100 | Quality Level 200 | Quality Level 200 | Quality Level 200 |
hcodes
Hazard Classifications
Aquatic Chronic 4
Classe di stoccaggio
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Scegli una delle versioni più recenti:
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
Xing et al.
Advanced drug delivery reviews, 30(1-3), 219-227 (2000-06-06)
Cationic liposomes have been used in many gene therapy approaches. The advantages of low toxicity, lack of immunological response, and easy preparation using cationic liposomes make multiple administrations possible, which may overcome the disadvantage of low transfection efficiency. Cationic liposomes
Minghan Shi et al.
Journal of nanobiotechnology, 16(1), 77-77 (2018-10-07)
Effectiveness of chemotherapy for treating glioblastoma (GBM) brain tumors is hampered by the blood-brain barrier which limits the entry into the brain of most drugs from the blood. To bypass this barrier, convection-enhanced delivery (CED) was proposed to directly inject
Dennis Christensen et al.
Expert review of vaccines, 10(4), 513-521 (2011-04-22)
The application of cationic liposomes as vaccine delivery systems and adjuvants has been investigated extensively over the last few decades. However, cationic liposomes are, in general, not sufficiently immunostimulatory, which is why the combination of liposomes with immunostimulating ligands has
Numero articolo commerciale globale
| SKU | GTIN |
|---|---|
| 92243-100MG | 04061833073742 |
| 92243-500MG | 04061833073759 |



